Key clinical point: Dupilumab appears safe and effective in adolescents with atopic dermatitis.
Major finding: At 1 year of treatment, about two-thirds of adolescent patients showed 50% or greater improvement in the Eczema Area and Severity Index score.
Study details: Phase 2a and phase 3 open-label studies of 40 adolescents with moderate to severe AD
Disclosures: Sanofi and Regeneron Pharmaceuticals sponsored the study. The lead author’s disclosures included those related to Sanofi Genzyme and Regeneron; other authors included employees of the companies.
Cork M et al. Br J Dermatol. 2019 Oct 9. doi: 10.1111/bjd.18476.